Tysabri Cost Data Shows Up To $23,274 Benefit Over Other MS Therapies
This article was originally published in The Pink Sheet Daily
Biogen Idec/Elan report data showing a treatment cost benefit with Tysabri based on multiple sclerosis relapses avoided.
You may also be interested in...
Biogen Idec/Elan's multiple sclerosis therapy Tysabri is available in the U.S. through a single distributor: AmerisourceBergen Specialty Group division ICS
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.
The start-up will secure $70m from Genentech, after closing a series B financing, while it moves its first CAR-T program into the clinic for ovarian cancer later this year.